Efficacy and safety of PARP inhibitors monotherapy or combination therapy with anti-angiogenics in ovarian cancer: a network meta-analysis

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-01-26
DOI
https://doi.org/10.3389/fonc.2025.1713163
Primary Topic
PARP inhibition in cancer therapy
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy and safety of PARP inhibitors monotherapy or combination therapy with anti-angiogenics in ovarian cancer: a network meta-analysis

Zhe Wang, Wenjiang Cao, Tongtong Ren, Xinchun Wang et al.
Frontiers in Oncology
PARP inhibition in cancer therapy
article

Efficacy and safety of PARP inhibitors monotherapy or combination therapy with anti-angiogenics in ovarian cancer: a network meta-analysis

Zhe Wang, Wenjiang Cao, Tongtong Ren, Xinchun Wang, Lisha Tang, Yuan Liu
article en

Abstract

No abstract available for this paper.
Frontiers in OncologyVol. 15
Shihezi University (CN), People's Liberation Army No. 150 Hospital (CN), First Affiliated Hospital of Shihezi University Medical College (CN), Chinese People's Liberation Army (CN), Kangda College of Nanjing Medical University, Nanjing Medical University (CN)
National Natural Science Foundation of China, Nanjing Medical University, Xinjiang Production and Construction Corps
Good health and well-being
Openalex Percentile: Top 78%
PARP inhibition in cancer therapy
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.